Healthcare -
Biotechnology - NASDAQ - US
$ 23.5077
-0.927 %
$ 439 M
Market Cap
-7.15
P/E
1. INTRINSIC VALUE
Balance Sheet
Tectonic Therapeutic, Inc.
| Current Assets | 147 M |
| Cash & Short-Term Investments | 141 M |
| Receivables | 0 |
| Other Current Assets | 5.62 M |
| Non-Current Assets | 6.05 M |
| Long-Term Investments | 0 |
| PP&E | 5.3 M |
| Other Non-Current Assets | 743 K |
| Current Liabilities | 11.6 M |
| Accounts Payable | 976 K |
| Short-Term Debt | 2.78 M |
| Other Current Liabilities | 7.85 M |
| Non-Current Liabilities | 519 K |
| Long-Term Debt | 519 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Tectonic Therapeutic, Inc.
| Revenue | 0 |
| Cost Of Revenue | 1.64 M |
| Gross Profit | -1.64 M |
| Operating Expenses | 56.4 M |
| Operating Income | -58 M |
| Other Expenses | -33 K |
| Net Income | -58 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Tectonic Therapeutic, Inc.
| Net Income | -58 M |
| Depreciation & Amortization | 1.64 M |
| Capital Expenditures | -156 K |
| Stock-Based Compensation | 3.49 M |
| Change in Working Capital | -10.3 M |
| Others | -4.81 M |
| Free Cash Flow | -59.2 M |
Wall Street Analysts Price Targets
Tectonic Therapeutic, Inc.
TECX has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
TECX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Tectonic Therapeutic, Inc.
Sold
0-3 MONTHS
8.55 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
10.8 M USD 1
0-3 MONTHS
40.2 M USD 2
3-6 MONTHS
11.5 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), which are being presented in a late-breaking, oral session at the European Society of Cardiology (ESC) Heart Failure 2025 Congress being held in Belgrade, Serbia. The results include the full cohort of 19 patients in Part A of the Phase 1b trial of TX45, Tectonic's lead asset and a long-acting relaxin therapy. Interim data for 16 patients in the Phase 1b trial was previously reported in a press release on January 30, 2025.
globenewswire.com
- 1 month ago
Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?
The consensus price target hints at a 258.5% upside potential for Tectonic Therapeutic, Inc. (TECX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
- 1 month ago
Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights
WATERTOWN, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the first quarter ended March 31, 2025, and provided an overview of recent business highlights.
globenewswire.com
- 1 month ago
Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF
We initiate a Buy rating on Tectonic Therapeutic due to promising data for TX45. TX45 showed positive interim Phase 1b results, but the APEX Phase 2 trial with 180 patients will be crucial for validating its efficacy and safety. TX2100 targets hereditary hemorrhagic telangiectasia with promising preclinical data, aiming for a Phase 1 launch in late 2025 or early 2026.
seekingalpha.com
- 1 month ago
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
WATERTOWN, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an overview of recent business highlights.
globenewswire.com
- 2 months ago
Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data
Positive interim results released from phase 1b study, using TX45 for the treatment of patients with pulmonary hypertension heart failure with preserved ejection fraction. Data from phase 1b study using TX45 for the treatment of patients with pulmonary hypertension heart failure with reduced ejection fraction, expected in 2nd half of 2025. In the 7 major markets, the heart failure market is expected to grow to $33.7 billion in 2032.
seekingalpha.com
- 4 months ago
Tectonic Announces $185 Million Private Placement
WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $185.0 million.
globenewswire.com
- 4 months ago
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein. The interim data showed that a single intravenous dose of TX45 resulted in meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”). In the trial, TX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events.
globenewswire.com
- 4 months ago
Tectonic Therapeutic: Protein Engineering Platform For GPCRs
Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension, showing promise in early clinical trials. TX45's extended half-life and monthly dosing address limitations of native relaxin, positioning it as a potential best-in-class therapeutic. With favorable phase 1a data and ongoing phase 1b and 2 trials, Tectonic's TX45 could become a market leader, potentially attracting interest from potential biopharma acquirers.
seekingalpha.com
- 5 months ago
Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024
WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024 from 4:00 PM to 6:00 PM ET. To register, click here .
globenewswire.com
- 6 months ago
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Piper Sandler 36th Annual Healthcare Conference being held in New York on December 3-5, 2024.
globenewswire.com
- 6 months ago
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
WATERTOWN, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced detailed results from the Phase 1a clinical trial of its lead asset, TX45, a long-acting, Fc-relaxin fusion protein. The poster will be presented at the American Heart Association (AHA) Scientific Sessions on November 16, 2024 from 3-4pm EST in Chicago, Illinois. Favorable topline results from the TX45 Phase 1a clinical trial were announced on September 19, 2024, along with the dose selection for the TX45 APEX Phase 2 trial that is currently underway in patients with PH-HFpEF.
globenewswire.com
- 7 months ago
8. Profile
Summary
Tectonic Therapeutic, Inc. TECX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 439 M
Dividend Yield
0.00%
Description
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Contact
490 Arsenal Way, Watertown, MA, 02472
https://tectonictx.com
IPO
Date
None
Employees
51
Officers
Dr. Peter McNamara Ph.D.
Chief Scientific Officer
John Diener
Senior Vice President of Antibody Engineering & Protein Sciences
Dr. Marcella Kuhlman Ruddy M.D., M.S.
Chief Medical Officer
Dr. Marc Schwabish Ph.D.
Chief Business Officer
Mr. Barry Rubenstein M.S.
Senior Vice President of People & Culture
Dr. Timothy A. Springer M.B.A., Ph.D.
Co-Founder & Independent Director
Mr. Daniel Lochner M.B.A.
Chief Financial Officer
Dr. Alise S. Reicin M.D., Ph.D.
President, Chief Executive Officer, Secretary & Director
Mr. Anthony Muslin M.D.
Chief Development Officer